Nuvalent, Inc. (NUVL)
NUVL Stock Price Chart
Explore Nuvalent, Inc. interactive price chart. Choose custom timeframes to analyze NUVL price movements and trends.
NUVL Company Profile
Discover essential business fundamentals and corporate details for Nuvalent, Inc. (NUVL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
29 Jul 2021
Employees
162.00
Website
https://www.nuvalent.comCEO
James R. Porter
Description
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
NUVL Financial Timeline
Browse a chronological timeline of Nuvalent, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$1.44, while revenue estimate is $245.46k.
Earnings released on 7 May 2026
EPS came in at -$1.39 falling short of the estimated -$1.35 by -2.96%.
Earnings released on 26 Feb 2026
EPS came in at -$1.29 surpassing the estimated -$1.48 by +12.84%.
Earnings released on 30 Oct 2025
EPS came in at -$1.70 falling short of the estimated -$1.39 by -22.30%.
Earnings released on 7 Aug 2025
EPS came in at -$1.31 falling short of the estimated -$1.27 by -3.15%.
Earnings released on 8 May 2025
EPS came in at -$1.18 falling short of the estimated -$1.14 by -3.51%.
Earnings released on 27 Feb 2025
EPS came in at -$1.05 falling short of the estimated -$1.04 by -0.96%.
Earnings released on 12 Nov 2024
EPS came in at -$1.28 falling short of the estimated -$0.93 by -37.03%.
Earnings released on 8 Aug 2024
EPS came in at -$0.88 falling short of the estimated -$0.76 by -15.79%.
Earnings released on 9 May 2024
EPS came in at -$0.69 falling short of the estimated -$0.67 by -2.99%.
Earnings released on 27 Feb 2024
EPS came in at -$0.62 falling short of the estimated -$0.59 by -5.08%.
Earnings released on 14 Nov 2023
EPS came in at -$0.59 matching the estimated -$0.59.
Earnings released on 10 Aug 2023
EPS came in at -$0.51 surpassing the estimated -$0.53 by +3.77%.
Earnings released on 11 May 2023
EPS came in at -$0.44 surpassing the estimated -$0.51 by +13.73%.
Earnings released on 16 Mar 2023
EPS came in at -$0.49 falling short of the estimated -$0.43 by -13.95%.
Earnings released on 10 Nov 2022
EPS came in at -$0.41 surpassing the estimated -$0.46 by +10.87%.
Earnings released on 10 Aug 2022
EPS came in at -$0.38 surpassing the estimated -$0.43 by +11.63%.
Earnings released on 12 May 2022
EPS came in at -$0.36 surpassing the estimated -$0.40 by +10.00%.
Earnings released on 29 Mar 2022
EPS came in at -$0.36 falling short of the estimated -$0.32 by -12.50%, while revenue for the quarter reached $2.43m .
Earnings released on 10 Nov 2021
EPS came in at -$0.39 falling short of the estimated -$0.25 by -56.00%.
Earnings released on 8 Sept 2021
EPS came in at -$3.17 falling short of the estimated -$0.19 by -1.57k%.
Earnings released on 30 Jul 2021
EPS came in at -$0.30 .
NUVL Stock Performance
Access detailed NUVL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
